Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Want to cut your energy bills? Here’s how five experts are doing it 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
JERSEY, Channel Islands, May 31, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 3:00 p.m. Eastern Time at the Grand Hyatt New York.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
